Clinical Trial

Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA

Completed
View on ClinicalTrials.gov →
Summary
This retrospective observational study evaluated the diagnostic and predictive value of serum Inhibin B (INHB), follicle-stimulating hormone (FSH), and the INHB/FSH ratio in differentiating histopathological subtypes of non-obstructive azoospermia (NOA) in men undergoing microdissection testicular sperm extraction (micro-TESE). Seventy-three patients treated at a single tertiary referral center between January 2023 and September 2025 were included. Hormonal parameters were assessed preoperatively, and histopathological findings were categorized into five groups (SCOS, EMA, LMA, HSG, NS). The INHB/FSH ratio demonstrated significant discriminative ability across histopathological patterns and showed strong predictive performance in ROC and regression analyses. These findings suggest that the INHB/FSH ratio may serve as a practical, non-invasive biomarker for estimating testicular pathology severity in NOA patients.
Trial Details
NCT Number NCT07415928
Lead Sponsor Elazıg Fethi Sekin Sehir Hastanesi
Conditions Azoospermia, Nonobstructive, Non-obstructive Azoospermia
Enrollment 73 participants
Start Date 2026-01-10
Primary Completion 2026-02-02 (estimated)
Study Completion 2026-02-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-17